Extensive research from clinical-epidemiological studies and cell culture experiments consistently indicate that MALAT1 plays a role as a tumor promoter in GBMs, with its inhibition resulting in reduced tumor growth in a large number of preclinical GBM models. Here, MALAT1 is linked to neoplasm.